The latest price target for Sangamo Therapeutics Inc (OTC:SGMO) was reported by HC Wainwright & Co. on February 10, 2026. The analyst firm set a price target for $10.00 expecting SGMO to fall to within 12 months (a possible NaN% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Sangamo Therapeutics Inc (OTC:SGMO) was provided by HC Wainwright & Co., and Sangamo Therapeutics Inc reiterated their buy rating.

There is no last upgrade for Sangamo Therapeutics Inc

The last downgrade for Sangamo Therapeutics Inc happened on November 7, 2025 when Barclays changed their price target from $5 to $1 for Sangamo Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics Inc, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics Inc was filed on February 10, 2026 so you should expect the next rating to be made available sometime around February 10, 2027.

While ratings are subjective and will change, the latest Sangamo Therapeutics Inc (SGMO) rating was a reiterated with a price target of $10.00 to $10.00. The current price Sangamo Therapeutics Inc (SGMO) is trading at is $undefined, which is out of the analyst’s predicted range.